secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001823239-25-000062
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q1 revenue $46.9M (-27% YoY), net loss $(52.9)M, adj EBITDA $(10.5)M
----------------------------------------------------------------------------

- Revenue $46.9M vs $64.2M in Q1 2024; net loss $(52.9)M includes $12.4M goodwill impairment.
- Adjusted EBITDA fell to $(10.5)M from $7.8M in prior-year quarter.
- Nucleic Acid Production revenue $28.8M (-37.5% YoY) on lack of high-volume CleanCap orders; Biologics Safety Testing $18.1M (flat YoY).
- Full-year 2025 revenue guidance maintained at $185M-$205M, excluding potential high-volume CleanCap vaccine orders.
- Base business (ex CleanCap vaccine) grew >$4M sequentially from Q4 2024, per CEO Trey Martin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000062/0001823239-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000062/mrvi-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001823239-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer